Severe acute pancreatitis
Conditions
Interventions
Thoracic epidural analgesia group:None
Non-thoracic epidural analgesia group:None
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.18 Age <=90 years old; 2. Stay in the ICU for more than 24 hours of treatment; 3. Clearly diagnosed as a SAP patient.
Exclusion criteria
Exclusion criteria: 1.Patients with pancreatitis during pregnancy; 2. Patients with chronic heart failure at grade IV, uremic stage of chronic renal failure, decompensated stage of chronic liver cirrhosis, and long-term need for home oxygen therapy due to chronic respiratory diseases; 3. Patients with concurrent acute coronary syndrome, acute pulmonary embolism, and acute cerebrovascular accident; 4. Patients with concurrent malignant tumors or severe immune deficiency diseases; 5. Patients who are transferred to other hospitals halfway or give up treatment; 6. Patients or their agents who refused to participate in this study; 7. Patients with insufficient clinical data or missing key data; 8. Patients with contraindications related to TEA operations (e.g. Patients with hypovolemia or shock, those with epidural infection due to infection or bacteremia at the puncture site, those in a hypocoagulable state or those who have not stopped using anticoagulant drugs for a sufficient period of time recently, those who have undergone surgery at the puncture site, those with trauma or deformity, those with low back pain that may worsen after anesthesia, and those with mental illness, severe neurosis and other uncooperative patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prognostic indicators: 28 days after admission, all-cause mortality, length of stay in ICU, total length of stay, total hospitalization cost, duration of mechanical ventilation, duration of high-flow oxygen inhalation.;Anesthetic use data: During ICU treatment: the use of midazolam, propofol injection, butorphenol hydrochloride injection, hydromorphone hydrochloride injection; | — |
Secondary
| Measure | Time frame |
|---|---|
| General baseline data of patients: age, gender, source of visit, cause of SAP, combined underlying diseases, time from onset to admission, time from onset to admission to ICU, and imaging pathological characteristics;Laboratory test data: at admission to ICU and on day 5 of admission to ICU: Total white blood cell count, absolute value of neutrophil, absolute value of lymphocyte, neutrophil to lymphocyte ratio, calcium, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine, urea, estimated glomerular filtration rate, prothrombin time activity, activated partial thromboplastin time, fibrinogen, D-D polymers, hypersensitive C-reactive protein, down Procalcin, oxygen and index, resid;Severity assessment data: Ranson score, Acute physiological and chronic health score (APACHE II score), CT Severity Index score (CTSI score), intra-abdominal pressure (IAP) at admission to ICU and day 5 in ICU;Complications: Existing complications at ICU admission and new complications during ICU treatment: Acute respiratory distress syndrome (ARDS), acute kidney injury, AKI), septic shock, severe pneumonia, acute liver injury, coagulation disorder, necrotic accumulation, pseudocysts, pancreaticogenic abdominal hemorrhage or hematoma formation, pancreaticogenic portal hypertension, deep vein thrombosis;Data on clinical treatment needs: During ICU treatment: Occurrence of high flow oxygen, mechanical ventilation, percutaneous thoracoabdominal drainage, continuous bedside renal replacement therapy (CRRT), interventional hemostasis or cyst drainage, bedside plasma exchange, vasoactive drugs, endoscopic cyst drainage or hemostasis, open surgery, bedside bronchoscopy, use of carbapenem antibiotics, and positive etiological culture; | — |
Countries
China
Contacts
Public ContactHongmei Huang
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed